I-Mab and Jumpcan To Announce its Strategic Commercial Partnership on Eftansomatropin Alfa - Special Call Transcript
Good morning and good evening. Thank you for standing by. This is Tianyi Zhang, IR Director of I-Mab Biopharma. Thank you for joining the conference call, cohosted by I-Mab Biopharma and Jumpcan Pharmaceutical.
Earlier today, I-Mab and Jumpcan jointly announced that the 2 companies have established a commercial partnership on the only clinical stage pure protein-based long-acting growth hormone, eftansomatropin alfa, which is also known as TJ101.
Today's conference, we will have the management team from both I-Mab and Jumpcan to give you more insights of the commercial partnership. Joining me today on the call from I-Mab's senior management team includes Dr. Jingwu Zang, Founder and Chairman of I-Mab; Mr. John Long, Chief Financial Officer of I-Mab; Mr. Jielun Zhu, Chief Strategy Officer of I-Mab; Dr. Weiming Tang, Chief Business Officer of I-Mab; and Mr. Yifei Zhu, Chief Commercial Officer of I-Mab. We also have management team from Jumpcan Pharmaceutical. They are Dr. Jun Liu, General Manager of Jumpcan Pharmaceuticals; and Mr. Wei Cao,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
